Search Results - "FAIRLAMB, Alan H."

Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis by Patterson, Stephen, Fairlamb, Alan H

“…Interest in nitroheterocyclic drugs for the treatment of infectious diseases has undergone a resurgence in recent years. Here we review the current status of…”
Get more information

Drug Resistance in Leishmaniasis by CROFT, Simon L, SUNDAR, Shyam, FAIRLAMB, Alan H

“…Classifications Services CMR Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Validation of Trypanosoma cruzi inactivation techniques for laboratory use by MacLean, Lorna M, Ariyanayagam, Mark, Sastry, Lalitha, Paterson, Christy, De Rycker, Manu, Fairlamb, Alan H

“…Trypanosoma cruzi (T. cruzi) is the causative agent of Chagas' disease, a parasitic infection responsible for significant morbidity and mortality in Latin…”
Get full text

Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania by Wyllie, Susan, Roberts, Adam J, Norval, Suzanne, Patterson, Stephen, Foth, Bernardo J, Berriman, Matthew, Read, Kevin D, Fairlamb, Alan H

“…Drug discovery pipelines for the "neglected diseases" are now heavily populated with nitroheterocyclic compounds. Recently, the bicyclic nitro-compounds…”
Get full text

Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation by WYLLIE, Susan, PATTERSON, Stephen, FAIRLAMB, Alan H

“…OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay by DE RYCKER, Manu, HALLYBURTON, Irene, FAIRLAMB, Alan H, GRAY, David W, THOMAS, John, CAMPBELL, Lorna, WYLLIE, Susan, JOSHI, Dhananjay, CAMERON, Scott, GILBERT, Ian H, WYATT, Paul G, FREARSON, Julie A

“…OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Chemotherapy of human African trypanosomiasis: current and future prospects by Fairlamb, Alan H.

“…Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the…”
Get full text

The critical role of mode of action studies in kinetoplastid drug discovery by Fairlamb, Alan H, Wyllie, Susan

“…Understanding the target and mode of action of compounds identified by phenotypic screening can greatly facilitate the process of drug discovery and…”
Get full text

Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis by Perry, Meghan R., Wyllie, Susan, Raab, Andrea, Feldmann, Joerg, Fairlamb, Alan H.

“…The Indian subcontinent is the only region where arsenic contamination of drinking water coexists with widespread resistance to antimonial drugs that are used…”
Get full text

Norspermidine Is Not a Self-Produced Trigger for Biofilm Disassembly by Hobley, Laura, Kim, Sok Ho, Maezato, Yukari, Wyllie, Susan, Fairlamb, Alan H., Stanley-Wall, Nicola R., Michael, Anthony J.

“…Formation of Bacillus subtilis biofilms, consisting of cells encapsulated within an extracellular matrix of exopolysaccharide and protein, requires the…”
Get full text

Drug resistance in eukaryotic microorganisms by Fairlamb, Alan H., Gow, Neil A. R., Matthews, Keith R., Waters, Andrew P.

“…Eukaryotic microbial pathogens are major contributors to illness and death globally. Although much of their impact can be controlled by drug therapy as with…”
Get full text

Target validation: linking target and chemical properties to desired product profile by Wyatt, Paul G, Gilbert, Ian H, Read, Kevin D, Fairlamb, Alan H

“…The discovery of drugs is a lengthy, high-risk and expensive business taking at least 12 years and is estimated to cost upwards of US$800 million for each drug…”
Get more information

N -myristoyltransferase inhibitors as new leads to treat sleeping sickness by Cleghorn, Laura A. T, Torrie, Leah S, Frearson, Julie A, Guther, M. Lucia S, Smid, Ondrej, Smith, Deborah F, Stojanovski, Laste, Wilkinson, Anthony J, Wyatt, Paul G, Brannigan, James A, Hui, Raymond, Brand, Stephen, Raimi, Olawale G, Brenk, Ruth, Robinson, David A, Hodgkinson, Michael, Ferguson, Michael A. J, Hallyburton, Irene, Mpamhanga, Chidochangu P, Gilbert, Ian H, McElroy, Stuart P, van Aalten, Daan M. F, Qiu, Wei, Read, Kevin D, Price, Helen P, Fairlamb, Alan H

“…African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma brucei spp., is responsible for ∼30,000 deaths each year. Available…”
Get full text

Allosteric Activation of Trypanosomatid Deoxyhypusine Synthase by a Catalytically Dead Paralog by Nguyen, Suong, Jones, Deuan C., Wyllie, Susan, Fairlamb, Alan H., Phillips, Margaret A.

“…Polyamine biosynthesis is a key drug target in African trypanosomes. The “resurrection drug” eflornithine (difluoromethylornithine), which is used clinically…”
Get full text

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis by Patterson, Stephen, Wyllie, Susan, Norval, Suzanne, Stojanovski, Laste, Simeons, Frederick Rc, Auer, Jennifer L, Osuna-Cabello, Maria, Read, Kevin D, Fairlamb, Alan H

“…There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683),…”
Get full text

Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani by Wyllie, Susan, Cunningham, Mark L., Fairlamb, Alan H.

“…Despite extensive use of antimonial compounds in the treatment of leishmaniasis, their mode of action remains uncertain. Here we show that trivalent antimony…”
Get full text

Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis by SOKOLOVA, Antoaneta Y, WILLIE, Susan, PATTERSON, Stephen, OZA, Sandra L, READ, Kevin D, FAIRLAMB, Alan H

“…OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis by PATTERSON, Stephen, WYLLIE, Susan, STOJANOVSKI, Laste, PERRY, Meghan R, SIMEONS, Frederick R. C, NORVAL, Suzanne, OSUNA-CABELLO, Maria, DE RYCKER, Manu, READ, Kevin D, FAIRLAMB, Alan H

“…OA  Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase by Roberts, Adam J, Torrie, Leah S, Wyllie, Susan, Fairlamb, Alan H

“…Co- and post-translational N-myristoylation is known to play a role in the correct subcellular localization of specific proteins in eukaryotes. The enzyme that…”
Get more information

Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study by Perry, Meghan R, Prajapati, Vijay K, Menten, Joris, Raab, Andrea, Feldmann, Joerg, Chakraborti, Dipankar, Sundar, Shyam, Fairlamb, Alan H, Boelaert, Marleen, Picado, Albert

“…In the late twentieth century, emergence of high rates of treatment failure with antimonial compounds (SSG) for visceral leishmaniasis (VL) caused a public…”
Get full text